DUBLIN, Ireland—Allergan (NYSE: AGN) posted a whopping 116 percent increase in net revenue to $5.76 billion for the quarter ended June 30, 2015, compared to $2.67 billion in the second quarter 2014, a result of both its recent acquisition by Actavis and strong sales of its key products.

Brent Saunders, CEO and president of Allergan said, "In our first full quarter as a combined company, Allergan delivered exceptional results. Our performance was powered by operational excellence and double-digit growth across our brands and global generics businesses, while continuing outstanding momentum on the integration of Actavis and Allergan. We also achieved important R&D milestones that will help fuel both our branded and generics businesses in the future."

For the second quarter 2015, non-GAAP gross margin was 72.3 percent compared to 56.3 percent in the second quarter of 2014, reflecting the impact of the Allergan acquisition. Total non-GAAP SG&A as a percent of non-GAAP revenue for the second quarter 2015 was 21.7 percent compared to 18.7 percent in the prior year period.

For the second quarter 2015, non-GAAP R&D spending was $406.0 million compared to $184.8 million in the prior year. Adjusted EBITDA increased 203 percent to $2.61 billion in the second quarter of 2015, compared to $862.0 million for the second quarter 2014. Cash flow from operations for the second quarter of 2015 was $1.4 billion and cash and marketable securities were $1.5 billion as of June 30, 2015.

For the second quarter 2015, total global branded product revenues were $3.7 billion versus $637 million in the prior year quarter. Allergan reported that Restasis, an ophthalmic drug that increases tear production in dry eye patients, generated $325 million in revenue during the quarter, making it one of the company’s top performing branded products.